Natalia Baran, Leading Attending, Assistant Professor at the University Clinic for Hematology, Insel Group, and Adjunct Assistant Professor at the University of South Dakota, Sanford School of Medicine, shared a post on LinkedIn:
“Our latest study published in Frontiers in Pharmacology introduces a novel anti-B7 H3 Affibody with strong potential for AML therapy.
Designed to target B7-H3-positive AML cells, this conjugate shows potent antiproliferative and cell death-inducing activity in vitro.
Read more about this promising therapeutic approach
Congratulations to first author Andrei-Mihai Vasilescu and to Prof. Stefan Szedlacsek as well as to all co-authors. Stefan Szedlacsek thank you for inviting me to collaborate on this exciting project, am very grateful and thrilled to see this work published.”
Title: A novel cytotoxic anti-B7-H3 affibody with therapeutic potential in acute myeloid leukemia
Authors: Andrei-Mihai Vasilescu, Adina-Gabriela Vasilescu, Livia Elena Sima, Cristian V. A. Munteanu, Natalia Baran, Ștefan-Eugen Szedlacsek.
Read the full article on Frontiers.
Read more from Natalia Baran on OncoDaily.